THE COST ANALYSIS OF BRONCHODILATOR PRESCRIPTIONS FOR TREATMENT OF STABLE COPD IN UKRAINE

Author(s)

Tolubaiev V, Zalis'ka ODanylo Halytsky Lviv national medical university, Lviv, Ukraine

OBJECTIVES: To analyze the GP’s prescriptions of bronchodilators for managing the patients with stable COPD, to compare the prescriptions with Ukrainian National COPD Management Guidelines. And we estimated the annual costs for bronchodilators were used most frequently. METHODS: The analysis of prescription habits based on data from outpatient personal medical cards of 103 patients with COPD (2nd Municipal Clinic, Bila Tserkva, Ukraine), focused on bronchodilators as central medications for symptomatic treatment. Among 103 patients 15 were with mild COPD, 75 with moderate and 13 with severe (according to GOLD). The prescriptions for regular treatment were compared with national guidelines. Annual medications costs were calculated based on the number of medicines units for 24 hour bronchodilation during a year, multiplied by the one unit price in UAH (1 EUR =10.05 UAH). RESULTS: Regular basis was prescribed to 87 patients. Among 87 prescriptions 13.7% were long-acting inhaled bronchodilators or combinations, 86.3% were short-acting inhaled bronchodilators, methylexanthines or combinations. Ranking to a number of medicines were most frequently prescribed: 56.8% fixed combination Ipratropium/Fenoterol, 10.2% Tiotropium, 9.1% Fenoterol, 7.9% Salbutamol. Annual costs for these bronchodilators were: 1206.0, 6262.0, 1303.0 and 275.0 UAH, respectively. CONCLUSIONS: The most frequently prescribed bronchodilator was Ipratropium/Fenoterol. It’s available during decades and inexpensively. But its basis requires triple daily medication, in consequence of that persistency rate might be reduced with effectiveness reducing, respectively. Tiotropium ranked second in the prescription frequency. It has duration of action of more than 24 hours, high effectiveness and safety levels but gets 6262.0 UAH annually. So the affordability of a bronchodilator is weighty criterion for Ukrainian GP’s prescriptions. But medications costs must be scrupulously compared with effectiveness for their including to the national formulary and reimbursement decision-making.

Conference/Value in Health Info

2010-11, ISPOR Europe 2010, Prague, Czech Republic

Value in Health, Vol. 13, No. 7 (November 2010)

Code

PRS12

Topic

Economic Evaluation

Topic Subcategory

Cost-comparison, Effectiveness, Utility, Benefit Analysis

Disease

Respiratory-Related Disorders

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×